REG-4basebio Plc: Result of Extraordinary General Meeting

4BasebioAnnouncement

10/10/2025 11:45

10 October 2025

4basebio PLC

("4basebio" or the "Company")

Result of Extraordinary General Meeting

Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led
provider of novel synthetic DNA products and a non-viral, thermostable nucleic
acid delivery platform announces that all of the resolutions proposed at its
Extraordinary General Meeting held earlier today were duly passed. 

For further enquiries, please contact:

 4basebio PLC                                      +44 (0)12 2396 7943  
 Dr. Heikki Lanckriet, CEO                                              
 Cairn Financial Advisers LLP (Nominated Adviser)  +44 (0)20 7213 0880  
 Jo Turner / Sandy Jamieson / Ed Downes                                 
 Cavendish Capital Markets Limited (Joint Broker)  +44 (0)20 7220 0500  
 Geoff Nash / Nigel Birks                                               
 RBC Capital Markets (Joint Broker)                +44 (0)20 7653 4000  
 Kathryn Deegan / Matthew Coakes                                        
                                                                        

Notes to Editors

About 4basebio

4basebio (AIM: 4BB) is an innovation driven life biotechnology company focused
on accelerating the development of advanced therapy medicinal products (ATMPs)
through its high-performance synthetic DNA products and non-viral, cell
targeting nucleic acid delivery platform. The Company’s objective is to
become a market leader in the manufacture and supply of high-quality synthetic
DNA products for research, therapeutic and pharmacological use as well as
development of target specific non-viral vectors for the efficient delivery of
payloads in patients.



Copyright (c) 2025 PR Newswire Association,LLC. All Rights Reserved